(Print or Type Responses)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response..

5. Relationship of Reporting Person(s) to Issuer

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * FROST PHILLIP MD ET AL				2. Issuer Name and Ticker or Trading Symbol Opko Health, Inc. [OPK]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _X_ Director _X_ 10% Owner				
(Last) (First) (Middle) 4400 BISCAYNE BLVD				3. Date of Earliest Transaction (Month/Day/Year) 09/18/2009							X Officer (give title below) Other (specify below) CEO & Chairman				
(Street) MIAMI, FL 33137-3227				4. If Amendment, Date Original Filed(Month/Day/Year)						_	6. Individual or Joint/Group Filing(Check Applicable Line) Form filed by One Reporting Person X. Form filed by More than One Reporting Person				
(City) (State) (Zip)			(Zip)	Table I - Non-Derivative Securities Acqui						ies Acquire	ired, Disposed of, or Beneficially Owned				
1.Title of Sect (Instr. 3)	urity		2. Transaction Date (Month/Day/Year)		n Da	Year)	Frans	(A)	Securities A	equired 5. Or 5. Tr	Amount of Sowned Following ansaction(s) anstr. 3 and 4)	ecurities Be	neficially 6	o. Ownership Form:	Beneficial Ownership
Reminder: Re	port on a sep	earate line for each o	Table II -	Derivativo	e Sec	curities A	cquii	Persons in this fo displays	rm are not	required y valid OM neficially O	to respond IB control n	unless the	tion contain e form	ed SEC	474 (9-02)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, i	4. f Transaction Code		5. Number of		6. Date Exercisable and Expiration Date		T. Title and Amount of Underlying Securities (Instr. 3 and 4)			9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)	Ownershi Form of Derivativ Security: Direct (D or Indirect	(Instr. 4)
				Code	v	(A)	(D)	Date Exercisabl	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	(Instr. 4)	
Series D Cumulative Convertible Preferred Stock		09/18/2009		A		252,019)	(1)	(1)	Common Stock	2,520,190 (2)	\$ 24.8	252,019	I	See Footnote
Warrant (Right to Buy)	\$ 2.48	09/18/2009		A		630,048	3	<u>(4)</u>	<u>(4)</u>	Common	630,048	\$ 0	630,048	I	See Footnote

Reporting Owners

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
FROST PHILLIP MD ET AL 4400 BISCAYNE BLVD MIAMI, FL 33137-3227	X	X	CEO & Chairman			
Frost Gamma Investments Trust 4400 BISCAYNE BOULEVARD MIAMI, FL 33137		X				

Signatures

/s/ Phillip Frost MD	09/22/2009
Signature of Reporting Person	Date
/s/ Phillip Frost MD, as trustee	09/22/2009
Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The convertible preferred stock is convertible at any time, at the holder's option, and has no expiration date.
- (2) Subject to adjustment upon certain events.

252,019 shares of Series D Cumulative Convertible Preferred Stock owned by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma,

- (3) Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
- (4) The warrants are immediately convertible and expire five years following the date of issuance.
 - Warrants to purchase 630,048 shares of common stock owned by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive
- beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. the general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole

 (5) shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is also the sole shareholder of Frost-Nevada Corporation. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Remarks:

Exhibit List:

Exhibit 99 - Joint Filer Information

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

JOINT FILER INFORMATION

Name:	Frost Gamma	Investments Trust

Address: 4400 Biscayne Blvd

Miami, FL 33137

Designated Filer: Phillip Frost, M.D.

Issuer Name and Ticker Symbol: OPKO Health, Inc. (OPK)

Date of Earliest Transaction: September 18, 2009

Relationship to Issuer: 10% Owner

FROST GAMMA INVESTMENTS TRUST

by: <u>/s/ Phillip Frost MD, as trustee</u> Phillip Frost, M.D., Trustee